Laws · Ongoing coverage · 2,859 words

DEA Medical Marijuana Policy: Scheduling, Enforcement, and State Market Impact

This hub explains how the Drug Enforcement Administration shapes the legal landscape for medical marijuana in the United States. It covers marijuana's Schedule I classification under the Controlled Substances Act, the ongoing rescheduling process, the DEA's registration and enforcement authority, and the gap between federal prohibition and state-legal medical programs. It also tracks how new DEA policies, including those that licensed operators say threaten medical marijuana markets, affect patients, dispensaries, and compliance obligations. Updated as agency actions, court rulings, and industry responses develop.

Last updated November 20, 2026 · 0 updates since publication
Panoramic view of the Berlin Federal Chancellery during twilight, showcasing modern architectural design.
The DEA enforces the Controlled Substances Act, under which marijuana remains federally illegal even though most states permit medical use. DEA policy governs scheduling recommendations, registrations for research and manufacture, and enforcement priorities. Changes to that policy can directly affect the operations, compliance risk, and viability of state-licensed medical marijuana markets.

Executive Summary

The Drug Enforcement Administration controls the federal legal status of medical marijuana through the Controlled Substances Act, and a new DEA policy reported in November 2026 has companies warning that state medical markets face fresh legal exposure. Law360 reported on November 19, 2026, that businesses say the policy imperils medical marijuana markets. This hub explains the framework behind that warning and what operators, patients, and investors should track as details emerge.

A caveat first: the Law360 article sits behind a paywall, and this foundation page does not reproduce its contents beyond the headline and the companies' stated concern. Specific provisions of the policy should be verified against primary DEA and Federal Register documents, linked in the further reading section below.

The structural facts are stable. Marijuana remains a Schedule I controlled substance under 21 U.S.C. § 812, a classification that federal law reserves for drugs with "no currently accepted medical use." Yet a large majority of U.S. states have enacted medical cannabis programs, creating a standing conflict between state law and federal law. Congress has softened that conflict through appropriations riders, and the DEA has historically exercised enforcement discretion. Any DEA policy shift that narrows that discretion, changes registration rules, or alters the rescheduling track lands directly on state-licensed operators.

The rescheduling process, the DEA's registration authority over research and manufacture, and the interplay with FDA drug approval all shape how a new policy would operate. This page lays out that machinery, profiles the players, and flags the decision points ahead. Dated updates will be appended below as the policy's text, litigation, and market reaction become clear.

Why This Matters

Medical marijuana touches millions of patients, thousands of licensed businesses, and billions of dollars in annual state-regulated sales, all resting on a federal enforcement posture the DEA can tighten or relax.

Stakeholders fall into five groups:

  • Patients who rely on state medical programs for conditions such as chronic pain, epilepsy, PTSD, and chemotherapy-related nausea, and who face the risk of supply disruption or higher prices if operators retrench.
  • Licensed operators, including multistate operators (MSOs) and single-state cultivators, processors, and dispensaries, whose banking, insurance, and tax positions all hinge on federal tolerance.
  • Investors and lenders who price cannabis equities and debt on the assumption that federal reform trends toward relaxation rather than restriction.
  • State regulators in places like California, Florida, and Ohio who administer medical programs without federal sanction.
  • Federal agencies, principally the DEA and FDA, that must reconcile the Controlled Substances Act with a de facto state-level medical market.

The tax angle compounds the stakes. Because marijuana is Schedule I, state-licensed businesses cannot deduct ordinary operating expenses under Internal Revenue Code Section 280E, which produces effective tax rates far above those of comparable industries. Rescheduling to Schedule III would remove that burden; a restrictive policy moves the opposite direction.

For operators, the practical question is binary in its consequences: does the new DEA policy change enforcement risk, or does it change process risk, such as registration, rescheduling timelines, or product definitions? The answer determines whether the response is legal, financial, or operational.

Background and History

The DEA's authority over medical marijuana descends from the 1970 Controlled Substances Act, and five decades of petitions, court fights, and appropriations riders explain why the agency's policy choices carry such weight today.

1970: The Controlled Substances Act

Congress passed the Controlled Substances Act (CSA) in 1970 and placed marijuana in Schedule I under 21 U.S.C. § 812, pending the findings of a national commission. The Shafer Commission later recommended decriminalizing personal possession, but the scheduling stayed. The DEA was created in 1973 and inherited enforcement of the schedules.

1970s-1980s: Early Rescheduling Petitions

The National Organization for the Reform of Marijuana Laws petitioned in 1972 to reschedule marijuana. The petition dragged on for roughly two decades, producing a 1988 recommendation from DEA Administrative Law Judge Francis Young that marijuana be moved to Schedule II. The DEA Administrator rejected that recommendation, establishing a pattern: administrative law judges (ALJs) and scientists sometimes favored reform while agency leadership did not.

1996: California's Proposition 215

California voters approved the Compassionate Use Act, the first state medical marijuana law in modern times. The federal response was hostile at first, including threats against physicians who recommended cannabis, which the courts limited in Conant v. Walters. Other states followed in the late 1990s and 2000s.

2001-2005: Federal Supremacy Affirmed

In United States v. Oakland Cannabis Buyers' Cooperative (2001), the Supreme Court rejected a medical necessity defense to CSA manufacturing and distribution charges. In Gonzales v. Raich (2005), the Court held that Congress could reach even home-grown, state-legal medical marijuana under the Commerce Clause. Those rulings are why state legalization never displaced federal law.

2009-2013: The Ogden and Cole Memos

The Justice Department's 2009 Ogden memo and 2013 Cole memo told federal prosecutors to deprioritize enforcement against state-compliant actors, subject to eight priorities such as preventing sales to minors and diversion to other states. Those memos gave operators practical comfort without changing the law. The Cole memo was rescinded in January 2018 by then-Attorney General Jeff Sessions, restoring prosecutorial discretion to individual U.S. Attorneys.

2014: The Rohrabacher-Farr Amendment

Congress added an appropriations rider, now commonly called Rohrabacher-Blumenauer, barring the Justice Department from spending funds to interfere with state medical marijuana programs. The Ninth Circuit's United States v. McIntosh (2016) read the rider to restrict prosecutions of compliant actors. The rider must be renewed in each spending bill, which makes it a recurring point of leverage.

2016-2020: Research Registration and the DEA Monopoly

The DEA in 2016 declined two rescheduling petitions but announced it would expand the number of registered manufacturers of research-grade marijuana, ending the University of Mississippi's decades-long monopoly on federally sanctioned supply. Applications sat for years. In 2020 the DEA proposed registering additional growers, a process that remained slow and contested.

2018: Hemp Carve-Out

The 2018 Farm Bill removed hemp, defined as cannabis with no more than 0.3 percent delta-9 THC by dry weight, from the CSA definition of marijuana. The carve-out created a parallel hemp-derived market and prompted lasting disputes over THCA and intoxicating hemp products, issues that now intersect with DEA policy.

2022-2024: The Biden Review and the NPRM

In October 2022, President Biden directed the Department of Health and Human Services (HHS) and the Attorney General to review marijuana's scheduling. In August 2023, HHS recommended moving marijuana to Schedule III. In May 2024, the DEA published a notice of proposed rulemaking (NPRM) to do so, and a hearing before an ALJ was scheduled. The process stalled amid procedural disputes over participant selection and appeals, and the hearing did not proceed as planned.

2025-2026: Executive Action and Continued Uncertainty

The rescheduling track remained contested into 2025 and 2026 as the administration, the DEA, and stakeholders disputed the pathway. The November 2026 Law360 report that a new DEA policy imperils medical marijuana markets arrives against this backdrop of unresolved rescheduling. Readers should confirm the policy's exact nature, whether guidance, rule, or enforcement directive, from primary sources.

Key Players

A small set of federal agencies, state regulators, trade groups, and litigants determine how DEA medical marijuana policy translates into real-world market outcomes.

Drug Enforcement Administration

The DEA administers the CSA schedules, registers manufacturers and researchers, and holds final rulemaking authority over rescheduling after an HHS recommendation. Its Administrator and its Office of the Administrative Law Judges control process and timing.

Food and Drug Administration

The FDA conducts the scientific and medical evaluation that HHS forwards to the DEA, and it approves drugs for medical use. FDA-approved cannabinoid medicines, such as Epidiolex (cannabidiol, or CBD) and dronabinol, sit in different schedules than plant marijuana, which illustrates the gap between plant-based state medicine and federal drug approval.

Department of Justice

The Justice Department sets prosecutorial priorities and defends the CSA in court. The appropriations rider constrains its spending on interference with state medical programs.

Multistate Operators and Trade Groups

Large MSOs and associations such as the National Cannabis Industry Association and the U.S. Cannabis Council lobby, litigate, and comment in rulemakings. They are the companies most likely to be quoted in coverage like the Law360 report on the new policy.

Patient Advocates and Opposition

Patient groups such as Americans for Safe Access press for protections for medical access. Opposition comes from groups such as Smart Approaches to Marijuana, which argue that rescheduling or relaxed enforcement would increase youth use and commercial exploitation. Both sides file comments and testify in DEA proceedings.

State Regulators

Agencies in California, Florida, Ohio, New York, and other states license operators, test products, and register patients. They are the first responders to any federal change.

Legal and Regulatory Framework

The legal architecture combines the Controlled Substances Act, DEA rulemaking procedure, appropriations riders, and constitutional federalism, and each layer limits or amplifies what a new DEA policy can do.

The Controlled Substances Act

Under 21 U.S.C. § 812, Schedule I requires a high potential for abuse, no currently accepted medical use, and a lack of accepted safety under medical supervision. Section 811 gives the Attorney General, delegated to the DEA, authority to add, remove, or transfer substances after obtaining a scientific and medical evaluation from HHS. The HHS findings on scientific questions are binding on the DEA, a point that shaped the 2023 recommendation's weight.

Rulemaking Procedure

Rescheduling through formal rulemaking under 21 U.S.C. § 811(a) requires notice, an opportunity for a hearing on the record, and final agency action reviewable in a federal court of appeals. A policy statement or guidance carries less legal force than a rule but can still change enforcement behavior and registration practice.

Registration Authority

Anyone who manufactures, distributes, or dispenses a controlled substance must register with the DEA under 21 U.S.C. § 822. No state-licensed marijuana business holds a DEA registration for plant marijuana, which is why state programs operate outside the federal system. Changes to registration policy, such as for research growers or for Schedule III handling, would reshape who may lawfully touch the plant.

Appropriations Riders

The Rohrabacher-Blumenauer language prohibits the Justice Department from using funds to prevent states from implementing medical marijuana laws. Courts have read it to bar prosecution of compliant actors, though not of those who stray from state rules. Because Congress renews it annually, its status is a recurring variable.

Federalism and the Anti-Commandeering Doctrine

States cannot be forced to criminalize marijuana, and the federal government cannot compel state enforcement of the CSA. But Raich confirms that federal prohibition persists regardless of state law. The result is a dual system where compliance with state law offers no federal defense.

Section 280E

280E denies business deductions to traffickers in Schedule I and II substances. The IRS and courts have applied it to state-legal dispensaries, and rescheduling to Schedule III would end that application, which makes any DEA scheduling move a direct tax event.

State-by-State Breakdown

Because state medical programs differ sharply in size, structure, and exposure, a federal DEA policy shift would hit each market differently. The table below summarizes illustrative features; operators should confirm current possession limits and program rules with each state regulator.

StateProgram TypeFederal Exposure Notes
CaliforniaMedical since 1996; adult-use market since 2016Largest legal market; heavy MSO presence; high 280E burden
FloridaMedical-only; vertically integrated licenseesLargest medical-only market; policy changes affect it most directly
OhioMedical and adult-useRegulated dispensary model; sensitive to registration changes
New YorkMedical and adult-useLarge patient base; evolving licensing
PennsylvaniaMedical-onlySignificant medical market dependent on state license stability

California

California's medical framework dates to Proposition 215 in 1996 and now operates alongside adult-use sales. A federal policy narrowing tolerance would pressure its large licensed base, especially operators with interstate ambitions.

Florida

Florida runs a medical-only market dominated by vertically integrated licensees. Because there is no adult-use cushion, a federal change affecting medical operators would transmit more directly to Florida revenue and patient access than to mixed markets.

Ohio

Ohio licenses cultivators, processors, and dispensaries under state oversight and, like other states, has no federal registration. Registration or scheduling changes would require compliance reviews across its supply chain.

New York

New York's medical program serves a large patient population within a growing legal market. State regulators would likely issue guidance to licensees quickly if federal policy changed.

Pennsylvania

Pennsylvania's medical-only structure resembles Florida's exposure profile, with a patient-centered market whose stability depends on continued federal restraint.

Market and Business Implications

For operators and investors, DEA policy risk shows up in three places: tax treatment, access to capital and banking, and the viability of interstate and research strategies.

On tax, the 280E burden is the largest recurring federal cost. Industry advocates have argued for years that rescheduling to Schedule III would materially improve cash flow, and public company filings routinely cite 280E in their risk factors. A policy that stalls or reverses rescheduling prolongs that cost.

On capital, MSO equity and debt valuations embed assumptions about federal reform. Headlines like the Law360 report that a DEA policy imperils medical markets can widen spreads and chill lending, particularly for smaller operators who depend on private credit. Banking access, already fragile, depends on guidance from federal financial regulators and on risk tolerance among institutions; heightened DEA hostility raises compliance costs for any bank serving the sector.

On wholesale pricing, no policy by itself sets a price, but supply shocks do. If a rule restricts product categories or imposes registration burdens that force marginal cultivators out, wholesale flower prices in constrained medical markets could firm. Conversely, uncertainty that depresses investment can delay capacity and tighten supply later. Readers should track state wholesale reports rather than infer prices from federal headlines.

Operators should consider a practical checklist:

  1. Obtain the policy text and classify it: rule, guidance, enforcement memo, or registration notice.
  2. Map each license and product line to the provisions that touch it.
  3. Review loan covenants and insurance policies for federal-change clauses.
  4. Coordinate with state regulators and trade associations on comments and litigation.
  5. Model cash flow with and without 280E relief.

What Experts Say

Legal and policy analysts generally agree that DEA action matters most through process: who controls scheduling, how registration works, and whether enforcement discretion narrows.

Cannabis attorneys have long said that the central risk in federal policy is not a sudden wave of prosecutions but the gradual narrowing of the practical space in which state-licensed businesses operate. Many point out that the HHS scientific recommendation is binding on the DEA for scientific questions, which constrains how far the agency can depart from the 2023 Schedule III finding if it returns to the formal track.

Reform advocates argue that restrictive policy undermines patient access and public health benefits documented in state programs, and they emphasize that rescheduling to Schedule III would not itself legalize state markets, because Schedule III drugs still require FDA approval and DEA registration. Opponents of loosening argue that a more permissive federal posture risks commercialization and higher use among youth, and they urge deliberate, evidence-based process.

Tax specialists note that even Schedule III status would leave open compliance questions around dispensing without FDA approval, a gap that policy and legislation, not scheduling alone, would need to close. Industry commentators quoted in coverage of the November 2026 policy, per Law360, said it imperils medical markets; those characterizations are the companies' own and should be weighed alongside the agency's stated rationale once available.

What's Next

The coming months turn on the policy's legal form, any court challenge, congressional appropriations language, and the status of the stalled rescheduling track.

Key decision points to watch:

  • Publication and text: Whether the policy appears in the Federal Register, as a DEA notice, or as internal guidance, which determines comment rights and judicial review.
  • Litigation: Petitions for review in a federal court of appeals or district court suits by operators and trade groups.
  • Appropriations: Whether the next spending bill preserves the medical marijuana rider and whether Congress adds language addressing DEA conduct.
  • Rescheduling track: Whether the DEA revives the ALJ hearing process or withdraws the 2024 NPRM.
  • State responses: Guidance from regulators in California, Florida, Ohio, New York, and Pennsylvania on compliance and patient continuity.

Scenarios range from a narrow, administrable policy with limited market effect, to a broad restriction triggering emergency litigation, to a reversal under political or judicial pressure. Operators should plan for the middle case: prolonged uncertainty, selective enforcement risk, and higher legal costs, while preserving the option value of a Schedule III outcome.

This hub will carry dated update sections as the policy's text, court filings, and market reactions become available.

Further Reading

  • Law360, "New DEA Policy Imperils Medical Marijuana Markets, Cos. Say" (November 19, 2026): https://news.google.com/rss/articles/CBMi0gFBVV95cUxQZ2JjYnoyTVZnWTU2eE9abWRYUV8xYkZ0MGwzeEplMnpvaUEtMFM5azVwN2FPOGNvcWVkbmQxMDl2YUxURFJPNDBiSjhERlF4N1h1NTNqQ1prandLVy16Qm02eTh4b3Z3UkpfOVRITlpaWXRXZWVZWHprczQzeVVPTW03eHVudDNSTmFwRUVhazZNdnUxZVZaQ2k4OUM1N3o4M2h4T3FpYmgtVmRrUkFZSEk1OVJtWjZKY19pYk5aOTZ6ZnpscVU4Y3N4eWVQUldsZVHSAXJBVV95cUxQRUphOW03OGZhN3lfMG90b3JfbUtxWExyOTlrd2hueUFIdXdseVRCSkdtYlBPNVJwdE0tSEoteGI1VFpiTlNTTUxyaWhOOFRqMkdqMXdINEFqOHp5Um5kTWhobEJUSDgyeWl6enRfTVpLOUE?oc=5
  • Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.law.cornell.edu/uscode/text/21/chapter-13/subchapter-I
  • 21 U.S.C. § 812 (Schedules of controlled substances): https://www.law.cornell.edu/uscode/text/21/812
  • Drug Enforcement Administration, Diversion Control Division, scheduling information: https://www.deadiversion.usdoj.gov/
  • Federal Register, DEA notice of proposed rulemaking on marijuana rescheduling (May 2024): https://www.federalregister.gov/
  • FDA, cannabis and cannabis-derived compounds guidance: https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process
  • Gonzales v. Raich, 545 U.S. 1 (2005): https://supreme.justia.com/cases/federal/us/545/1/
  • United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016): https://law.justia.com/cases/federal/appellate-courts/ca9/15-10117/15-10117-2016-08-16.html
  • Internal Revenue Code § 280E: https://www.law.cornell.edu/uscode/text/26/280E

Frequently asked questions

What is the DEA's role in medical marijuana policy?

The DEA enforces the federal Controlled Substances Act. It handles registrations for handling controlled substances, enforces federal drug law, and participates in scheduling decisions alongside the Department of Health and Human Services (HHS). It does not license state medical dispensaries, but its enforcement priorities and policy changes shape the risk environment for state-legal operators.

Is medical marijuana legal under federal law?

No. Marijuana is a Schedule I controlled substance under the Controlled Substances Act, meaning federal law treats it as having a high potential for abuse and no accepted medical use. Most states have nonetheless legalized medical marijuana under state law, creating a conflict between federal and state frameworks.

What does Schedule I mean for marijuana?

Schedule I is the most restrictive category of the Controlled Substances Act. Substances there are defined as having high abuse potential, no currently accepted medical use, and a lack of accepted safety under medical supervision. This classification limits clinical research, bars federal prescribing, and underlies federal tax and banking complications for the industry.

What is the status of marijuana rescheduling?

In 2024, the Department of Justice and DEA initiated a rulemaking to move marijuana to Schedule III, following an HHS recommendation. The process has involved administrative hearings and legal challenges and has repeatedly been delayed. Check the latest Federal Register notices and DEA announcements for current status, as outcomes may change.

How would Schedule III differ from Schedule I?

Schedule III substances are recognized as having accepted medical use and moderate-to-low potential for physical dependence. Rescheduling would ease research restrictions and could remove marijuana businesses from the tax burden of IRS Section 280E. It would not by itself legalize recreational use or automatically create a federal medical marijuana licensing system.

Why do companies say new DEA policy threatens medical marijuana markets?

As reported by Law360 in November 2026, companies argue a new DEA policy imperils medical marijuana markets. Industry concerns typically center on added registration, compliance, or enforcement requirements that could raise costs or create legal uncertainty for state-licensed operators. Review the underlying policy text and company filings for specifics.

Can the federal government prosecute state-legal medical marijuana operators?

Legally, yes, because federal law still prohibits marijuana. In practice, Congress has since 2014 attached an appropriations rider (Rohrabacher-Farr/Blumenauer) barring the Department of Justice from spending funds to interfere with state medical marijuana programs. The rider must be renewed in funding legislation and courts have limited its scope to compliant actors.

Does the DEA regulate marijuana research?

Yes. Researchers must obtain DEA registration to study Schedule I substances. Historically, federal research marijuana came from a single University of Mississippi supply. The DEA has taken steps to register additional domestic manufacturers, though the pace and scope of approvals have drawn criticism from researchers and applicants.

How does DEA policy affect medical marijuana patients?

Patients in state programs generally rely on state law for access, but federal policy can influence supply, pricing, and availability. Federal prohibition also affects patients in areas like firearm purchases, federal housing, and employment in federally regulated fields, regardless of state medical authorization.

What is the difference between medical marijuana and FDA-approved cannabinoid drugs?

FDA-approved products, such as Epidiolex (cannabidiol) and dronabinol-based medications, went through the formal drug approval process and are lawfully prescribed. State medical marijuana programs allow access to whole-plant cannabis that has not been FDA-approved. The DEA's scheduling treats these categories differently.

DEAreschedulingmedical marijuanaControlled Substances Actfederal policycannabis regulation
The CannIntel Daily

The cannabis newsletter you forward to your team.

Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.

No spam. Unsubscribe with one click. 21+ only.